Domo signs strategic collaboration agreement with AWS for AI solutions
In a recent filing with the Securities and Exchange Commission, Daxor Corp ’s (NYSE:NASDAQ:DXR) Chief Financial Officer, Michel Robert J, reported the purchase of 1,000 shares of the company’s common stock. The transaction, which took place on March 10, 2025, was valued at $8,000, with each share priced at $8.00 - sitting midway in the stock’s 52-week range of $6.55 to $10.00. According to InvestingPro data, the stock has shown contrarian market behavior with a beta of -0.53, often moving opposite to broader market trends. Following this acquisition, Michel’s total direct ownership of Daxor stock increased to 17,050 shares. This move comes as part of the routine insider transactions reported by company executives. While Daxor remains profitable over the last twelve months, InvestingPro analysis reveals the company faces some near-term challenges with short-term obligations exceeding liquid assets. For deeper insights into Daxor’s financial health and additional ProTips, investors can access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Daxor Corporation reported a remarkable 116.5% increase in revenue for the fourth quarter of 2024 compared to the previous year. The company also achieved a significant milestone by reaching cash flow breakeven in the first quarter of 2025, highlighting its financial stability. This growth is attributed to Daxor’s innovative product developments and strategic market expansion efforts. Additionally, the company is in the process of resubmitting its next-generation blood volume analyzer for FDA approval, aiming for a 510(k) clearance later in the year. The company has also expanded its market presence by signing new accounts and increasing kit sales.
Furthermore, Daxor is planning to transition from a 1940 Act to a 1934 Act company designation, which could enhance its market positioning. The company has secured additional contracts from the U.S. Department of Defense and received grants from the National Institutes of Health, contributing to its financial growth. Daxor’s plans for 2025 include launching a new product and acquiring a key supplier’s intellectual property to bring manufacturing in-house. These developments reflect Daxor’s commitment to advancing its technology and expanding its market reach.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.